Document is current
Any future updates will be listed below
-
Authors
Chen, Xuanrong https://orcid.org/0000-0003-4694-4579
Augello, Michael A.
Liu, Deli
Lin, Kevin
Hakansson, Alex
Sjöström, Martin https://orcid.org/0000-0002-2629-9966
Khani, Francesca https://orcid.org/0000-0001-7238-8604
Deonarine, Lesa D.
Liu, Yang https://orcid.org/0000-0003-1467-2652
Travascio-Green, Jaida
Wu, Jiansheng
Chan, Un In https://orcid.org/0000-0001-6095-3565
Owiredu, Jude
Loda, Massimo https://orcid.org/0000-0001-9674-8379
Feng, Felix Y. https://orcid.org/0000-0002-0963-7687
Robinson, Brian D. https://orcid.org/0000-0001-5374-890X
Davicioni, Elai
Sboner, Andrea https://orcid.org/0000-0001-6915-3070
Barbieri, Christopher E. https://orcid.org/0000-0002-0381-1947
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA215040 and R01CA233650)
Damon Runyon Cancer Research Foundation
MetLife Foundation
Prostate Cancer Foundation
- License Information
-
More Information
Article History
Received: 5 August 2024
Accepted: 18 October 2024
First Online: 13 December 2024
Competing interests
: M.S. reports grants from the Swedish Research Council, the Swedish Society of Medicine, and the Prostate Cancer Foundation during the conduct of the study. A.H., Y.L., and E.D. are employees of Veracyte, Inc. M.A.A. and D.L. are currently employees of Loxo Oncology. C.E.B. is a co-inventor on a patent issued to Weill Medical College of Cornell University on SPOP mutations in prostate cancer. F.Y.F. reports fees from Janssen Oncology, Bayer, PFS Genomics, Myovant Sciences, Roivant Sciences, Astellas Pharma, Foundation Medicine, Varian, Bristol Myers Squibb (BMS), Exact Sciences, BlueStar Genomics, Novartis, and Tempus; other support from Serimmune and Artera outside the submitted work. The authors declare no other potential competing interests.
